Irbesartan Al

Irbesartan, the active ingredient in Irbesartan Al, is an angiotensin II receptor antagonist presented as a tablet for oral use. It is employed to lower high blood pressure and to protect kidney function in patients with diabetic nephropathy, primarily in adult populations.

GNH USA supplies Irbesartan Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across EU and other markets, ensuring consistent batch release and on‑time delivery to meet clinical demand.

Irbesartan is an angiotensin II receptor blocker used in cardiovascular and renal disease management.

Hypertension: reduces systolic and diastolic blood pressure, improving overall cardiovascular risk. Diabetic nephropathy: slows progression of kidney damage in adults with type 2 diabetes, preserving renal function. Chronic kidney disease: helps control blood pressure and reduce proteinuria, supporting kidney health.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or tiredness - Nausea or abdominal discomfort - Upper respiratory tract infection - Back pain

Serious or Rare Side Effects: - Angio‑edema (swelling of face, lips, tongue, or throat) - Severe hypotension - Marked hyperkalaemia - Acute renal failure or worsening kidney function - Hepatic injury - Neutropenia or other severe blood dyscrasias

Before initiating therapy, consider the following precautions: - Pregnancy: Category D – avoid use during pregnancy due to fetal risk. - Renal impairment: monitor kidney function and adjust dose as needed. - Hepatic impairment: use with caution in patients with liver disease. - Hyperkalaemia: check serum potassium levels regularly, especially when combined with potassium‑sparing agents. - Concomitant potassium‑sparing diuretics or supplements: avoid or monitor closely to prevent excess potassium. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Irbesartan may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalaemia. - Concurrent use with ACE inhibitors or other ARBs: additive effect on blood pressure and potassium, risk of angio‑edema. - Potassium‑sparing diuretics or potassium supplements: may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely): - NSAIDs: can attenuate antihypertensive effect and affect renal function. - Lithium: may increase lithium levels, requiring serum monitoring. - Cyclosporine or tacrolimus: may raise blood pressure and affect renal clearance. - Thiazide diuretics: may enhance hypotensive effect, necessitating blood pressure checks.